Qualigen Therapeutics (QLGN) - צמיחת רווחים בשנה הנוכחית

Qualigen Therapeutics (QLGN) demonstrates high macro-resilience, as the development of cancer and viral drugs remains independent of economic cycles. Growth is driven by the implementation of the FastPack system and the progress of the QN-302 drug. The year-over-year earnings per share trend shows that the value is fixed at 0.00. However, the company is currently experiencing a technological stalemate with a limited set of preclinical studies.

Analyzing net income per share dynamics is critical for selecting assets with a high margin of safety. This indicator captures the annual percentage change in EPS, reflecting real business efficiency and the impact of operating expenses on final profitability. In the case of Qualigen Therapeutics (QLGN), the annual EPS change range demonstrates how R&D outsourcing and reliance on external vendors affect the financial result.